Chance (adjusted OR) of patients of different deprivation quintiles with CHD receiving different secondary preventive treatments at 31 March of successive years
| Year | Deprivation category quintile | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1* | 2 | 3 | 4 | 5 | ||||||
| Received treatment | Received treatment | Adjusted OR (95% CI)† | Received treatment | Adjusted OR (95% CI)† | Received treatment | Adjusted OR (95% CI)† | Received treatment | Adjusted OR (95% CI)† | ||
| *Reference group; †adjusted for age, practice differences, sex, and number of co-morbidities. | ||||||||||
| ACE inhibitors | ||||||||||
| 1997 | 115 (10.8%) | 111 (13.1%) | 1.0 (0.7 to 1.6) | 1321 (13.3%) | 1.3 (0.8 to 2.0) | 936 (12.1%) | 1.0 (0.6 to 1.5) | 618 (14.2%) | 1.0 (0.6 to 1.7) | |
| 1998 | 227 (16.3%) | 223 (17.1%) | 0.9 (0.6 to 1.2) | 309 (16.8%) | 1.0 (0.7 to 1.4) | 203 (14.9%) | 0.8 (0.6 to 1.1) | 145 (17.5%) | 0.9 (0.6 to 1.3) | |
| 1999 | 374 (20.0%) | 364 (19.7%) | 0.9 (0.7 to 1.1) | 558 (19.7%) | 0.9 (0.7 to 1.1) | 325 (17.8%) | 0.8 (0.6 to 1.0) | 210 (21.8%) | 1.0 (0.7 to 1.4) | |
| 2000 | 468 (25.2%) | 531 (24.3%) | 1.0 (0.8 to 1.2) | 801 (22.5%) | 0.9 (0.8 to 1.1) | 521 (22.0%) | 0.9 (0.7 to 1.1) | 259 (23.8%) | 1.0 (0.7 to 1.4) | |
| 2001 | 598 (24.8%) | 788 (31.1%) | 1.1 (0.9 to 1.3) | 1129 (27.2%) | 1.0 (0.8 to 1.2) | 775 (27.1%) | 1.0 (0.8 to 1.2) | 375 (29.6%) | 0.9 (0.7 to 1.2) | |
| 2002 | 735 (28.8%) | 971 (35.6%) | 1.1 (0.9 to 1.3) | 1459 (32.0%) | 1.1 (0.9 to 1.3) | 1010 (32.3%) | 1.1 (0.9 to 1.3) | 520 (36.6%) | 1.1 (0.8 to 1.4) | |
| Antiplatelets | ||||||||||
| 1997 | 317 (29.7%) | 241 (28.4%) | 1.0 (0.8 to 1.4) | 482 (36.5%) | 1.0 (0.7 to 1.3) | 362 (38.7%) | 1.1 (0.8 to 1.5) | 228 (36.9%) | 0.9 (0.6 to 1.2) | |
| 1998 | 588 (42.3%) | 598 (45.9%) | 1.0 (0.8 to 1.2) | 956 (51.9%) | 1.0 (0.8 to 1.3) | 690 (50.7%) | 1.0 (0.8 to 1.2) | 509 (61.4%) | 0.9 (0.6 to 1.2) | |
| 1999 | 1071 (57.3%) | 1048 (56.8%) | 1.1 (1.0 to 1.4) | 1819 (64.3%) | 1.1 (0.9 to 1.3) | 1097 (60.2%) | 1.0 (0.8 to 1.2) | 644 (66.9%) | 0.9 (0.7 to 1.3) | |
| 2000 | 1393 (75.0%) | 1377 (63.0%) | 1.0 (0.8 to 1.2) | 2536 (71.3%) | 1.0 (0.8 to 1.2) | 1592 (67.2%) | 1.0 (0.8 to 1.2) | 760 (69.9%) | 1.0 (0.7 to 1.2) | |
| 2001 | 1637 (67.8%) | 1666 (65.8%) | 1.1 (0.9 to 1.3) | 2996 (72.3%) | 1.1 (0.9 to 1.3) | 1953 (68.2%) | 1.1 (0.9 to 1.3) | 910 (71.9%) | 1.1 (0.9 to 1.5) | |
| 2002 | 1809 (70.9%) | 1877 (68.9%) | 1.0 (0.8 to 1.4) | 3372 (73.9%) | 1.0 (0.8 to 1.2) | 2188 (70.0%) | 1.0 (0.9 to 1.2) | 1033 (72.6%) | 1.1 (0.8 to 1.4) | |
| β Blockers | ||||||||||
| 1997 | 216 (20.2%) | 207 (24.4%) | 1.2 (0.9 to 1.7) | 317 (24.0%) | 1.0 (0.7 to 1.3) | 232 (24.8%) | 1.1 (0.8 to 1.5) | 128 (20.7%) | 0.8 (0.5 to 1.3) | |
| 1998 | 412 (29.6%) | 411 (31.5%) | 1.0 (0.8 to 1.3) | 608 (33.0%) | 1.0 (0.8 to 1.3) | 398 (29.2%) | 0.9 (0.7 to 1.1) | 272 (32.8%) | 0.9 (0.7 to 1.1) | |
| 1999 | 706 (37.8%) | 700 (37.9%) | 1.1 (0.9 to 1.4) | 1091 (38.5%) | 1.0 (0.8 to 1.2) | 665 (36.5%) | 1.0 (0.8 to 1.2) | 369 (38.3%) | 1.0 (0.8 to 1.3) | |
| 2000 | 910 (49.0%) | 917 (41.9%) | 1.1 (0.9 to 1.3) | 1565 (44.0%) | 1.0 (0.9 to 1.2) | 935 (39.5%) | 0.9 (0.8 to 1.1) | 455 (41.9%) | 1.0 (0.8 to 1.3) | |
| 2001 | 1107 (45.9%) | 1191 (47.1%) | 1.0 (0.9 to 1.4) | 1924 (46.4%) | 1.1 (0.9 to 1.2) | 1288 (45.0%) | 1.0 (0.9 to 1.2) | 559 (44.2%) | 1.1 (0.9 to 1.4) | |
| 2002 | 1200 (47.1%) | 1323 (48.6%) | 1.2 (1.0 to 1.4) | 2229 (48.8%) | 1.1 (1.0 to 1.3) | 1467 (46.9%) | 1.2 (1.0 to 1.3) | 655 (46.1%) | 1.1 (0.9 to 1.4) | |
| Statins | ||||||||||
| 1997 | 157 (14.7%) | 119 (14.0%) | 0.9 (0.6 to 1.3) | 187 (14.2%) | 0.9 (0.6 to 1.4) | 102 (10.9%) | 0.7 (0.5 to 1.1) | 101 (16.3%) | 0.7 (0.4 to 1.2) | |
| 1998 | 350 (25.2%) | 258 (19.8%) | 0.7 (0.5 to 0.9) | 439 (23.8%) | 0.8 (0.6 to 1.1) | 268 (19.7%) | 0.6 (0.5 to 0.8) | 203 (24.5%) | 0.6 (0.5 to 0.9) | |
| 1999 | 671 (35.9%) | 520 (28.1%) | 0.8 (0.7 to 1.0) | 886 (31.3%) | 0.8 (0.6 to 0.9) | 514 (28.2%) | 0.7 (0.6 to 0.9) | 302 (31.4%) | 0.7 (0.5 to 1.0) | |
| 2000 | 972 (52.3%) | 810 (37.0%) | 0.8 (0.7 to 1.0) | 1430 (40.2%) | 0.8 (0.7 to 0.9) | 923 (39.0%) | 0.7 (0.5 to 0.8) | 443 (40.8%) | 0.6 (0.5 to 0.8) | |
| 2001 | 1120 (46.4%) | 1016 (40.1%) | 0.9 (0.8 to 1.0) | 1722 (41.6%) | 0.8 (0.7 to 0.9) | 1152 (40.2%) | 0.8 (0.7 to 1.0) | 570 (45.1%) | 0.8 (0.6 to 1.0) | |
| 2002 | 1350 (52.9%) | 1326 (48.7%) | 0.9 (0.8 to 1.1) | 2322 (50.9%) | 0.9 (0.8 to 1.0) | 1511 (48.3%) | 0.9 (0.7 to 1.0) | 747 (52.5%) | 0.9 (0.7 to 1.1) | |
| At least one secondary preventive treatment | ||||||||||
| 1997 | 624 (58.4%) | 501 (58.9%) | 1.0 (0.8 to 1.3) | 888 (67.2%) | 0.9 (0.7 to 1.1) | 616 (65.8%) | 1.0 (0.8 to 1.3) | 422 (68.3%) | 0.8 (0.6 to 1.2) | |
| 1998 | 1021 (67.7%) | 945 (67.2%) | 0.9 (0.7 to 1.2) | 1482 (73.6%) | 0.9 (0.7 to 1.2) | 1009 (67.8%) | 0.8 (0.6 to 1.0) | 683 (76.8%) | 0.9 (0.7 to 1.3) | |
| 1999 | 1560 (79.1%) | 1482 (76.4%) | 1.2 (0.9 to 1.5) | 2441 (81.0%) | 1.0 (0.8 to 1.2) | 1514 (77.8%) | 1.0 (0.8 to 1.3) | 827 (80.1%) | 1.0 (0.7 to 1.4) | |
| 2000 | 1859 (83.5%) | 1883 (82.4%) | 1.1 (0.9 to 1.4) | 3214 (86.6%) | 1.1 (0.9 to 1.4) | 2042 (82.4%) | 1.0 (0.8 to 1.3) | 948 (83.3%) | 1.0 (0.7 to 1.4) | |
| 2001 | 2138 (85.3%) | 2244 (85.9%) | 1.4 (1.1 to 1.7) | 3751 (87.4%) | 1.1 (0.9 to 1.4) | 2537 (85.2%) | 1.2 (1.0 to 1.5) | 1126 (86.0%) | 1.3 (0.9 to 1.8) | |
| 2002 | 2301 (87.8%) | 2450 (87.3%) | 1.2 (1.0 to 1.6) | 4210 (89.4%) | 1.1 (0.9 to 1.4) | 2782 (86.1%) | 1.1 (0.9 to 1.4) | 1273 (86.4%) | 1.1 (0.8 to 1.5) | |